Processa Pharmaceuticals, Inc. PCSA NASDAQ

Processa Pharmaceuticals, Inc. (PCSA) generated $-11.39M in operating cash flow for fiscal year 2025. After capital expenditures of $5.00, free cash flow was $-11.39M.

Cash conversion ratio was 0.84x, suggesting some earnings are non-cash.

Criteria supported by this page:

• HEALTH (100/100, Pass) — demonstrate the company can comfortably service its debt
• MOAT (28/100, Fail) — limited free cash flow weakens the competitive position
• INCOME (?/100) — Cash conversion ratio was 0.84x suggests some earnings are non-cash items

Overall SharesGrow Score: 65/100 with 4/7 criteria passed.